A Phase I, Single and Multiple Ascending Dose Study of Topical Ladarixin Ophthalmic Solution in Healthy Volunteers for the Treatment of Ocular Inflammatory Conditions

The primary objective of this study is to evaluate the safety and pharmacokinetics of a single and multiple ascending dose of topical ladarixin ophthalmic solution in healthy volunteers. Assessment of these parameters is essential for determining the tolerability and systemic exposure profiles of the drug candidate prior to clinical application in ocular inflammatory conditions.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both males and females. The cohort belongs to an age range categorized by code 3. Participants are identified as a vulnerable population. No information was provided concerning ocular inflammatory conditions, lifestyle considerations, or specific selection processes.

This Phase 1 clinical trial is designed as a single and multiple ascending dose study to evaluate the safety and tolerability of topical ladarixin ophthalmic solution in healthy volunteers. The research methodology involves escalating doses to assess the pharmacological profile of the investigational product. The study protocol includes a screening visit to determine eligibility, followed by several study visits for dose administration and monitoring. Participants will undergo follow-up visits to evaluate clinical responses and an end-of-study visit to complete the assessment period. The total duration of participant involvement is determined by the specific dosing regimen assigned. Conditions leading to early termination from the study may include the occurrence of adverse events or failure to meet safety criteria. This study is relevant to the management of ocular inflammatory conditions.

The assessment of efficacy in this study focuses on ocular inflammatory conditions. No specific endpoints, measurement schedules, or assessment tools have been defined for the evaluation of clinical outcomes.